Clinical trial
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
NCT02052193 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
- Lead sponsor
- University Hospital Tuebingen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2014
- Completion date
- December 15, 2014
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic melanoma (carrying braf v600 mutation)